Society of Hematologic Oncology Insider news
In this SOHO Insider podcast, host Saad Usmani, MD, chief of the myeloma service at Memorial Sloan Kettering Cancer Center, spoke with Roberto Mina, MD, associate professor of hematology at Emory University, on news from the 2026 ASCO Annual Meeting. The conversation highlighted a presentation by Dr. Roberto Mina regarding the pivotal phase 3 MajesTEC-9 trial evaluating teclistamab monotherapy for patients with relapsed/refractory multiple myeloma who were previously exposed to lenalidomide and anti-CD38 antibodies Follow more news from ASCO here. [https://sohoinsider.com/category/meetings-conferences/asco-2026/]
15 episodios
Comentarios
0Sé la primera persona en comentar
¡Regístrate ahora y únete a la comunidad de Society of Hematologic Oncology Insider news!